OmsætningOverskudP/EKUVEBITUdbytteAktierMarkedsværdiGældForpligtelserEgenkapitalAAQSMedarbejdereROEROAROCE
Olink Holding AB (publ) Aktie

Olink Holding AB (publ) AAQS 2024

Olink Holding AB (publ) AAQS

4

Ticker

OLK

ISIN

US6807101000

WKN

A2QRZ6

Olink Holding AB (publ) har en aktuel AAQS på 4. En høj AAQS kan betragtes som et positivt tegn på, at virksomheden udvikler sig succesfuldt. Investorerne kan forvente, at virksomheden er på rette spor mod at skabe overskud. På den anden side er det vigtigt at betragte AAQS for aktien Olink Holding AB (publ) i forhold til de opnåede overskud og sammenligne med andre virksomheder i samme branche. En høj AAQS er ikke en absolut garanti for en positiv fremtid. Det er kun på den måde, man kan få et komplet billede af virksomhedens præstationer. For bedre at kunne vurdere virksomhedens udvikling er det vigtigt at betragte AAQS i sammenligning med andre virksomheder i samme branche. Generelt bør investorer altid betragte en virksomheds AAQS i sammenhæng med andre nøgletal som overskud, EBIT, cash flow og andre for at træffe en velbaseret investeringsbeslutning.

Olink Holding AB (publ) Aktienanalyse

Hvad gør Olink Holding AB (publ)?

The Olink Holding AB (publ) is a Swedish biotechnology company that was founded in Uppsala in 2004. The company specializes in the development and production of products for the life sciences and has made a name for itself in the industry in recent years. Olink's history began with an idea from researchers at Uppsala University who wanted to develop a more innovative method for measuring proteins that was more sensitive and required fewer reactive substances than traditional methods. In 2004, Olink introduced its first product, the ProteinChip system, to the market. The company grew rapidly, and in 2009, the first Olink product was launched in the USA. Since then, Olink has expanded its business model and now offers a range of products and services. The company's core technology is a unique approach to protein measurement that allows for the analysis of thousands of proteins in a single sample. Olink uses this technology in various fields, from preclinical research to clinical diagnostics. Olink has two main business areas: Life Science and Diagnostics. Olink's Life Science division provides research solutions for scientists in the fields of immunology, oncology, neurology, and infectious diseases. The company offers tests to measure proteins in body fluids such as blood, urine, and saliva that can be used as biomarkers for diseases. Olink's Diagnostics division focuses on developing tests for diseases such as cancer, cardiovascular diseases, and neurodegenerative diseases. The company works closely with clinical research and the pharmaceutical industry to develop new diagnostic tests and therapies. An example of an Olink product is the Precision Proteomics Protein Biomarker Discovery System. This system can be used for the discovery and development of biomarkers that can be used for the diagnosis, prediction, and monitoring of diseases. The company also offers a variety of protein analysis kits, including BeadChips, protein collection systems, and fluorescence imaging systems. In recent years, Olink has established itself as a key player in the field of proteomics and is constantly working to improve its technology and offerings. The company has formed partnerships with other companies and institutions to further develop its products and strengthen its market position. Overall, Olink is an emerging company that focuses on the development and production of products for the life sciences. The company has a unique technology and a wide range of products and services that can be used in various applications. Olink is expected to remain an important player in the industry in the future and contribute to further exploring the possibilities of proteomics. Olink Holding AB (publ) ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Ofte stillede spørgsmål om Olink Holding AB (publ) aktien

Aktiespareplaner tilbyder en attraktiv mulighed for investorer at opbygge formue på lang sigt. En af de største fordele er den såkaldte cost-average-effekt: Ved regelmæssigt at investere et fast beløb i aktier eller aktiefonde, køber man automatisk flere andele, når priserne er lave, og færre, når de er høje. Dette kan føre til en mere fordelagtig gennemsnitspris per andel over tid. Desuden giver aktiespareplaner også småinvestorer adgang til dyre aktier, da de kan deltage med små beløb. Den regelmæssige investering fremmer også en disciplineret investeringsstrategi og hjælper med at undgå følelsesladede beslutninger, som impulsiv køb eller salg. Derudover drager investorer fordel af den potentielle værdistigning af aktierne samt af udbytteudlodninger, der kan geninvesteres, hvilket forstærker renters rente effekten og dermed væksten af det investerede kapital.

Andere Kennzahlen von Olink Holding AB (publ)

Vores aktieanalyse af Olink Holding AB (publ) Omsætning-aktien indeholder vigtige finansielle nøgletal som omsætning, profit, P/E-ratioen, P/S-ratioen, EBIT samt informationer om udbytte. Desuden ser vi på aspekter som aktier, markedskapitalisering, gæld, egenkapital og forpligtelser hos Olink Holding AB (publ) Omsætning. Hvis du søger mere detaljerede oplysninger om disse emner, tilbyder vi på vores undersider omfattende analyser: